UnitedHealth Part D exec to depart
Executive Summary
Lois Quam, executive VP and president of the Public and Social Markets Group, is leaving the company to join investment banking and securities firm Piper Jaffray. She will be succeeded at United by Anthony Welters, previously president, CEO and co-founder of AmeriChoice, an administrator of public sector health care programs acquired by United in 2002. Quam, who has been with United for 18 years, led the start up of the company's market-leading Medicare Part D program. Also leaving United is Richard Anderson, exec VP and president of the Commercial Services Group. He will be succeeded by William Munsell, previously CEO of the company's Specialized Care Services group and chief administrative officer, United Healthcare...
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.